61results about How to "Low in lipids" patented technology

Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.

The present invention provides a method and apparatus for non-invasive reduction of excessive fat tissue by externally applying radio frequency (RF) electromagnetic (EM) waves adjusted to specific fat cells absorption frequency and electromagnetic propagation mode. Based on the performed experiments described further, the method and working apparatus has been invented that reduces fat layers without any medication, non-invasively through the intact skin. The invented method and apparatus facilitates the safe fat removal, and may lead to reduction and eradication of obesity and obesity associated diseases.

A system is provided for reducing lipid content of adipocytes in a body. The system includes an optical device configured to illuminate a region of the body at a selective peak wavelength and at a selective power density for a selective time period. The system also includes a controller connected to the optical device to determine the selective wavelength, the selective power density and the selective time period to stimulate lipolysis in the adipocytes. A system is also provided for reducing pain in the body. A method is also provided for reducing lipid content of adipocytes in the body.

The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and / or adipositas.

This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondrial respiratory chain. The present invention further includes pharmaceutical and / or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.

This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondrial respiratory chain. The present invention further includes pharmaceutical and / or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.

Irritation upon injection of a formulation containing propofol is reduced or substantially eliminated by administering a stable, sterile, and antimicrobial aqueous dispersion comprising a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm consisting essentially of about 1% to about 15% of propofol, up to about 7% of a propofol-soluble diluent, and about 0.8% to about 4% of a surface stabilizing amphiphilic aent. The aqueous phase includes a pharmaceutically acceptable water-soluble polyhydroxy tonicity modifier. The propofol-containing dispersion is devoid of additional bactericidal or bacteriostatic preservative agents.

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.

Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and / or nicotinic acid metabolites in combination with leucine and / or a leucine metabolite, with or without resveratrol.

Irritation upon injection of a formulation containing propofol is reduced or substantially eliminated by administering a stable, sterile, and antimicrobial aqueous dispersion comprising a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm consisting essentially of about 1% to about 15% of propofol, up to about 7% of a propofol-soluble diluent, and about 0.8% to about 4% of a surface stabilizing amphiphilic agent. The aqueous phase includes a pharmaceutically acceptable water-soluble polyhydroxy tonicity modifier. The propofol-containing dispersion is devoid of additional bactericidal or bacteriostatic preservative agents.

The invention discloses a preparation method of insoluble egg protein aggregate particles as well as an application thereof and belongs to the technical field of food. According to the invention, the egg protein aggregate particles are prepared by a combined heat treatment-mechanical shearing technology. This kind of particles have very good suspension stability in water, and have approximately spherical shapes whose granule particle sizes are 0.03-3 microns. Moreover, this kind of particles have very good wetting properties that the particles can be rapidly re-watered after drying, and the re-watered colloid has viscosity and smoothness similar to those of the fat as well as sensory properties of the colloid. The egg protein aggregate particles disclosed by the invention are used as emulsifiers, thickeners, brighteners, turbid agents and stabilizers in the food systems, including beverages, coffees, salad sauces, ice creams and the like, so as to maintain sensory properties of the systems while reducing fat contents and improving added nutritional values.

Described are a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. Solvents useful for extracting lipids from lipid-containing infectious viral organisms are employed thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. Provided are delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against a lipid-containing infectious viral organism or, as a therapeutic vaccine, to treat or alleviate infection by the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and / or one or more types of virus.

The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity. The present invention provides vaccine compositions, comprising these modified viral particles with reduced infectivity and enhanced antigenicity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and / or one or more types of virus.

Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.

This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain. The present invention further includes pharmaceutical and / or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.

The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and / or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.

Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and / or one or more types of virus.

The invention relates to an application of nicotinamide riboside in preparing drugs for treating non-alcoholic steatohepatitis. According to the application, a non-alcoholic steatohepatitis animal model is adopted to prove that the nicotinamide riboside is capable of reducing the liver lipid content, the liver inflammations and the liver fibrosis degree of the animal model and prompt that the nicotinamide riboside can be applied to preparing the drugs for treating the non-alcoholic steatohepatitis. The application of the nicotinamide riboside is expanded, a new way is provided for treating the non-alcoholic steatohepatitis, and therefore, the non-alcoholic steatohepatitis can be prevented and prognosed favorably.

The invention relates to a multifunctional beverage mainly comprising stachysfloridona and pu'er tea. The multifunctional drink comprises the following components in parts by weight: 10 to 90 parts of stachysfloridona extract, 10 to 90 parts of pu'er tea extract, 0 to 5 parts of flavoring agent, 0 to 2 parts of coloring agent, and 0 to 3 parts of preservative. In the multifunctional beverage, specific effects of the stachysfloridona and the pu'er tea are combined to achieve the synergistic effect in removing grease, clearing heat and reducing internal heat and disintoxicating; the raw materials belong to the food grade, do not have toxic or side effect, and have high safety, so the multifunctional beverage belongs to a green food, can be drunk constantly, and the processing process is simple. The multifunctional beverage can be used for removing grease and reducing harm of alcohol on a liver after being drunk for a long term; and meanwhile, the multifunctional beverage has the function of preventing and treating heart cerebrovascular diseases and liver diseases, is beneficial to body health, and accords with the requirement of healthy diet of people.

Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and / or one or more types of virus.

The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity. The present invention provides vaccine compositions, comprising these modified viral particles with reduced infectivity and enhanced antigenicity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and / or one or more types of virus.

The invention discloses a healthcare rice wine containing hawthorn fruits and coffee. The healthcare rice wine is composed of the following raw materials, by weight, 106-110 parts of rice, 8-10 parts of a hawthorn fruit, 6-7 parts of seaweed powder, 5-6 parts of coffee powder, 2-3 parts of Helianthus tuberosus, 3-4 parts of shaddock peel, 1-2 parts of lavender, 1-2 parts of common fenugreek seed, 1-2 parts of grape leaf, 4-5 parts of Radix Puerariae, 3-4 parts of Folium Perillae, 2-3 parts of purslane, 0.6-0.8 parts of citric acid and 10-13 parts of distiller's yeast. The healthcare rice wine containing hawthorn fruits and coffee produced in the invention breakthroughs the mouthfeel of a traditional rice wine, has a sweet and mellow fragrance, and has a very high healthcare value, and the seaweed powder can improve the human immunity, the anticancer activity and the antivirus activity. The polysaccharides of the seaweed powder can be combined with HIVs (human immunodeficiency viruses) to inactivate the HIVs in order to inhibit the virus replication and control AIDS; and the polysaccharides of the seaweed powder can also reduce the content of lipids causing atherosclerosis in the blood vessel, and treat cardiovascular and cerebrovascular diseases. The healthcare rice wine containing hawthorn fruits and coffee has the efficacies of appetite stimulating, digestion helping, blood circulation promoting, stasis eliminating, panting calming, phlegm reducing and the like, and is beneficial for the health of human bodies.

The invention discloses low-fat low-lipide-digestibility artificial butter. The low-fat low-lipide-digestibility artificial butter comprises the following components in parts by weight: 20-70 parts ofmicronized whey protein dispersed liquid, 10-30 parts of a xanthan gum system, and 10-60 parts of oil phase. The artificial butter not only has the characteristic of being low in fat (10-60%), but also can restrain contact of lipases and oil drops in digestive tracts of human bodies, and can prevent free fatty acids from being released, so that the lipide digestibility can be reduced. According to a method, whey protein and xanthan gum are used as raw materials, and damp and hot treatment, a micronizing technique, a compounding technique and an emulsifying homogenizing technique are adopted for preparing oil in water emulsion. The digestion suppression ratio of the artificial butter for lipide is as high as 60%. The low-fat low-lipide-digestibility artificial butter has smooth and soft mouth feel of butter, and white fine and smooth appearance, has similar processing characteristics of plasticity, stability and the like as cream sold in the market, and can be widely applied to processing of various foods through replacing cream.

The present invention relates to a composition containing extracts of Litchi seed for preventing or treating fatty liver or obesity. The composition of the present invention may induce the reduction of body fat mass, intestinal fat mass, total cholesterol concentration, levels of C / EBPa and PPAR?2 which are important factors of nuclear transcription in generating fat tissue, and the expression amounts of the aP2 gene which is the target gene of C / EBPa and PPAR?2, and eventually activate the prevention or treatment of obesity. The composition of the present invention may inhibit the progression of fatty liver diseases and treat same by maintaining the morphological, structural, and physiological functions of the liver, in addition to having the effect of preventing the development said fatty liver diseases.; Moreover, the composition of the present invention may improve fat accumulation in liver tissue by reducing the lipid content level in the liver tissue, and may have the effects of preventing the development of fatty liver, inhibiting the progression or improving the condition of patients by normalizing liver function marker enzyme expression. In addition, the present invention provides preliminary data showing that Litchi seed extracts, as a medicinal material and food, are efficacious in preventing and treating fatty liver diseases.

A fat reducing device and method utilizing optical emitters includes an array housing a plurality of optical emitters which are positioned to produce an optical output directed to a recipient, and a controller for instructing an operation of the array. The optical output being generated by a plurality of LED's cumulatively producing red light at approximately 635 nm, and at approximately 40,000 Lux, measurable at the array.A fat reducing device and method utilizing optical emitters also includes reducing lipid content of subcutaneous adipocytes using the optical emitting device, and delivering red light at approximately 313.6 Lux at a wavelength of approximately 635 nm for between 1 and 8 minutes, resulting in a total delivery of 2.88 Joules to the subcutaneous adipocytes of the target area of the recipient.